There are currently 48 active clinical trials seeking participants for Migraine research studies. The states with the highest number of trials for Migraine participants are Florida, California, Texas and New York.
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications
NCT06701526
Recruiting
The main goal of this trial is to learn whether eptinezumab improves migraine symptoms and quality of life of participants with migraine who did not perceive a sufficient improvement during previous treatment with therapies targeting calcitonin gene-related peptide (CGRP).
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
01/14/2025
Locations: Neuroscience Research Center, LLC, Canton, Ohio
Conditions: Migraine
Register for Updates
Overlapping Pain Trajectory Study
NCT05752396
Recruiting
The goal of this observational study is to learn about spatial and temporal nociceptive filtering in adolescents with chronic overlapping pain conditions (COPCs). The main questions it aims to answer are: 1. If spatial and temporal filtering of nociceptive information is disrupted in youth with COPCs compared with youth with localized pain conditions and healthy controls. 2. If disrupted nociceptive processing at baseline is associated with the transition from a single localized pain condition... Read More
Gender:
ALL
Ages:
Between 10 years and 19 years
Trial Updated:
08/20/2024
Locations: Cincinnati Children's Hospital, Cincinnati, Ohio
Conditions: Migraine, Musculoskeletal Pain, Functional Abdominal Pain Disorders, Chronic Pain, Widespread Chronic Pain, Low Back Pain, Healthy Volunteers
Register for Updates
Migraine Manager (R01)
NCT04567355
Recruiting
The objective of this trial is to test whether an online tailored intervention, Migraine Manager, is efficacious in improving headache outcomes compared to an attention control intervention in adolescents with migraines. We will conduct a randomized clinical trial to compare a sample of 80 youth (ages 11 to 17) with migraine receiving the online tailored adherence intervention to 80 youth in an attention control group. We will test whether adherence to healthy habit (hydration, regular meals, ex... Read More
Gender:
ALL
Ages:
Between 11 years and 17 years
Trial Updated:
03/25/2024
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Migraine, Migraine Disorders
Register for Updates
Intravenous Fluids in Pediatric Migraine
NCT06182098
Recruiting
The goal of this clinical trial is to compare intravenous (IV) fluids in pediatric patients with migraine. The main questions it aims to answer are: * Does a large amount of fluids (bolus) improve pain * Does a large amount of fluids (bolus) reduce admissions to the hospital for migraine Participants will be asked to report their pain and have vital signs checked every 30 minutes for two hours. Researchers will compare a large amount of fluids (bolus) to a small amount (half maintenance) to se... Read More
Gender:
ALL
Ages:
Between 5 years and 21 years
Trial Updated:
12/13/2023
Locations: Dayton Children's Hosptial, Dayton, Ohio
Conditions: Migraine, Migraine in Children
Register for Updates
A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine
NCT05164172
Recruiting
The main goal of the study is to assess the long-term safety of eptinezumab on children and adolescents ages 6 to 17 with chronic or episodic migraine.
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
04/10/2025
Locations: Ki Health Partners LLC DBA New England Institute for Clinical Research, Stamford, Connecticut +51 locations
Conditions: Migraine
Register for Updates
Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine
NCT03836040
Recruiting
This study will evaluate the efficacy and safety of erenumab in migraine prevention in children (6 to \<12 years) and adolescents (12 to \<18 years) with episodic migraine. The study hypothesis is that in pediatric participants with episodic migraine, the combined erenumab dose group has a greater reduction from baseline to week 9 through week 12 (month 3) in monthly migraine days (MMDs) when compared with placebo in the double-blind treatment phase (DBTP).
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
04/09/2025
Locations: Paradigm Clinical Research Center Inc, San Diego, California +119 locations
Conditions: Migraine
Register for Updates
Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects
NCT05156398
Recruiting
The purpose of this study is to compare the efficacy and safety of rimegepant to placebo as a preventative treatment for migraine in children and adolescents ≥ 6 to \<18 years with episodic migraine.
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
04/09/2025
Locations: The Belinga Clinic, Fort Smith, Arkansas +94 locations
Conditions: Migraine
Register for Updates
Study of Pregnancy Outcomes in Women Exposed to Rimegepant During Pregnancy
NCT05198245
Recruiting
The purpose of the study is to evaluate the risk of pregnancy and infant outcomes among women with migraine exposed to rimegepant during pregnancy and in two rimegepant unexposed comparator groups.
Gender:
FEMALE
Ages:
Between 16 years and 49 years
Trial Updated:
04/09/2025
Locations: Research Triangle Institute d/b/a RTI Health Solutions, Research Triangle Park, North Carolina
Conditions: Migraine
Register for Updates
Emgality for Migraine in Breastmilk
NCT06085144
Recruiting
The goal of this project is to evaluate galcanezumab transfer into maternal breastmilk, and to evaluate infant (growth, development, constipation, colic, infections) and maternal (headache) outcomes for dyads in which the mother was treated with galcanezumab and to compare outcomes for infants who were or were not breastfed after maternal treatment. In this prospective observational study, the study team proposes to prospectively collect serial milk samples from 30 adult women who are treated w... Read More
Gender:
FEMALE
Ages:
Between 18 years and 45 years
Trial Updated:
04/04/2025
Locations: University of California, San Francisco, San Francisco, California
Conditions: Migraine
Register for Updates
Safety and Efficacy Trial of MTX101 2mg for the Acute Treatment of Migraine in Adults
NCT06728553
Recruiting
The goal of this clinical trial is to learn if drug MTX101 works to treat acute migraine attacks in adults. It will also learn about the safety of the drug MTX101. The main questions it aims to answer are: Does the drug MTX101 lower headache pain for participants and the need to use a rescue medication? What side effects, if any, do participants have when taking the drug MTX101? Researchers will compare the drug MTX101 to a placebo (a look-alike substance that contains no drug) to see if the dr... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
03/26/2025
Locations: Kaizen Brain Center, La Jolla, California +6 locations
Conditions: Migraine
Register for Updates
Endometriosis and Migraine
NCT06785129
Recruiting
This study aims to determine differences in experimental pain and sex hormone levels between patients with migraine, patients with endometriosis, patients with migraine and endometriosis, and healthy controls. Participants will complete surveys, experimental pain paradigms and collection of samples for hormone analyses.
Gender:
FEMALE
Ages:
Between 12 years and 45 years
Trial Updated:
03/26/2025
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Migraine, Endometriosis
Register for Updates
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
NCT05125302
Recruiting
Migraine is a common neurological disorder typically characterized by attacks of throbbing, moderate to severe headache, often associated with nausea, vomiting, and sensitivity to light and sound. Migraine is extremely common and disabling in children. The purpose of this study is to evaluate how safe and effective ubrogepant is in the acute treatment of migraine in children and adolescents. Ubrogepant is a drug approved for the acute treatment of migraine in adults. Children and adolescents (a... Read More
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
03/25/2025
Locations: Rehabilitation & Neurological Services /ID# 229969, Huntsville, Alabama +110 locations
Conditions: Migraine
Register for Updates